Discriminating phenotypic signatures identified for tocilizumab, adalimumab, and tofacitinib monotherapy and their combinations with methotrexate
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1479-5876
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Anmerkungen
-
online resource.
- Erschienen in
-
Discriminating phenotypic signatures identified for tocilizumab, adalimumab, and tofacitinib monotherapy and their combinations with methotrexate ; volume:16 ; number:1 ; day:7 ; month:6 ; year:2018 ; pages:1-9 ; date:12.2018
Journal of translational medicine ; 16, Heft 1 (7.6.2018), 1-9, 12.2018
- Klassifikation
-
Medizin, Gesundheit
- Urheber
-
O’Mahony, Alison
- Beteiligte Personen und Organisationen
-
John, Markus R.
Cho, Hannah
Hashizume, Misato
Choy, Ernest H.
SpringerLink (Online service)
- DOI
-
10.1186/s12967-018-1532-5
- URN
-
urn:nbn:de:101:1-2018081217400627956234
- Rechteinformation
-
Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
- 15.08.2025, 07:25 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- O’Mahony, Alison
- John, Markus R.
- Cho, Hannah
- Hashizume, Misato
- Choy, Ernest H.
- SpringerLink (Online service)
Ähnliche Objekte (12)
Psoriasisarthritis: Radiologischer Progress unter Tofacitinib und Adalimumab
Differences and similarities in clinical and functional responses among patients receiving tofacitinib monotherapy, tofacitinib plus methotrexate, and adalimumab plus methotrexate: a post hoc analysis of data from ORAL Strategy
Sequential Tocilizumab and Tofacitinib Treatment for Systemic Juvenile Idiopathic Arthritis: a Case Report
Switching from adalimumab to tofacitinib in the treatment of patients with rheumatoid arthritis
Analysis of Disease Activity Metrics in a Methotrexate Withdrawal Study among Patients with Rheumatoid Arthritis Treated with Tofacitinib plus Methotrexate
Efficacy of tofacitinib in patients with rheumatoid arthritis stratified by background methotrexate dose group
Joint-level responses to tofacitinib and methotrexate: a post hoc analysis of data from ORAL Start
Clinical efficacy of abatacept compared to adalimumab and tocilizumab in rheumatoid arthritis patients with high disease activity
Methotrexate Discontinuation and Dose Decreases After Therapy With Tocilizumab: Results From the Corrona Rheumatoid Arthritis Registry
Addition or removal of concomitant methotrexate alters adalimumab effectiveness in rheumatoid arthritis but not psoriatic arthritis
Cost-effectiveness analysis of Tocilizumab compared to Adalimumab in the treatment of severe active rheumatoid arthritis in Iran
Methotrexate
Psoriasisarthritis: Radiologischer Progress unter Tofacitinib und Adalimumab
Differences and similarities in clinical and functional responses among patients receiving tofacitinib monotherapy, tofacitinib plus methotrexate, and adalimumab plus methotrexate: a post hoc analysis of data from ORAL Strategy
Sequential Tocilizumab and Tofacitinib Treatment for Systemic Juvenile Idiopathic Arthritis: a Case Report
Switching from adalimumab to tofacitinib in the treatment of patients with rheumatoid arthritis
Analysis of Disease Activity Metrics in a Methotrexate Withdrawal Study among Patients with Rheumatoid Arthritis Treated with Tofacitinib plus Methotrexate
Efficacy of tofacitinib in patients with rheumatoid arthritis stratified by background methotrexate dose group
Joint-level responses to tofacitinib and methotrexate: a post hoc analysis of data from ORAL Start
Clinical efficacy of abatacept compared to adalimumab and tocilizumab in rheumatoid arthritis patients with high disease activity
Methotrexate Discontinuation and Dose Decreases After Therapy With Tocilizumab: Results From the Corrona Rheumatoid Arthritis Registry
Addition or removal of concomitant methotrexate alters adalimumab effectiveness in rheumatoid arthritis but not psoriatic arthritis
Cost-effectiveness analysis of Tocilizumab compared to Adalimumab in the treatment of severe active rheumatoid arthritis in Iran
Methotrexate
Psoriasisarthritis: Radiologischer Progress unter Tofacitinib und Adalimumab
Differences and similarities in clinical and functional responses among patients receiving tofacitinib monotherapy, tofacitinib plus methotrexate, and adalimumab plus methotrexate: a post hoc analysis of data from ORAL Strategy
Sequential Tocilizumab and Tofacitinib Treatment for Systemic Juvenile Idiopathic Arthritis: a Case Report
Switching from adalimumab to tofacitinib in the treatment of patients with rheumatoid arthritis
Analysis of Disease Activity Metrics in a Methotrexate Withdrawal Study among Patients with Rheumatoid Arthritis Treated with Tofacitinib plus Methotrexate
Efficacy of tofacitinib in patients with rheumatoid arthritis stratified by background methotrexate dose group
Joint-level responses to tofacitinib and methotrexate: a post hoc analysis of data from ORAL Start
Clinical efficacy of abatacept compared to adalimumab and tocilizumab in rheumatoid arthritis patients with high disease activity
Methotrexate Discontinuation and Dose Decreases After Therapy With Tocilizumab: Results From the Corrona Rheumatoid Arthritis Registry
Addition or removal of concomitant methotrexate alters adalimumab effectiveness in rheumatoid arthritis but not psoriatic arthritis
Cost-effectiveness analysis of Tocilizumab compared to Adalimumab in the treatment of severe active rheumatoid arthritis in Iran